Femasys Inc (FEMY)

$0.57 +0.02 (3.27%)
Market Cap 33.22M
Revenue (ttm) 1.63M
Net Income (ttm) -18.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,154.60%
Debt to Equity Ratio 0.02
Volume 313,000
Avg Vol 773,636
Day's Range N/A - N/A
Shares Out 58.48M
Stochastic %K 79%
Beta -2.53
Analysts Strong Sell
Price Target $3.50

Company Profile

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-genera...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 770 500 3910
Fax: 404 581 5903
Address:
3950 Johns Creek Court, Suite 100, Suwanee, United States
isthisonebetter
isthisonebetter Mar. 15 at 3:59 PM
$FEMY they had $4.5 mln in cash sept 30 and that’s roughly their quarterly burn. Have they completed a raise recently?
0 · Reply
TwizzlersForSale
TwizzlersForSale Mar. 14 at 5:42 PM
FEMY is beginning to set off price alerts on trader trackers with the recent price action we saw last week. Could get ugly very quickly with shorts having to cover as attention towards FEMY retail is slowly ramping up. Very nasty week/s ahead could trigger off short squeeze on catalysts or any updates from company. Stay tuned $FEMY
1 · Reply
steve04240
steve04240 Mar. 14 at 4:05 PM
$FEMY
0 · Reply
frchmn
frchmn Mar. 14 at 9:54 AM
$BRTX something is brewing here, similar to $SRXH and $FEMY . The 1H chart is telling. I have bags in all 3 after cutting some of my other bags.
0 · Reply
frchmn
frchmn Mar. 13 at 5:02 PM
$FEMY looks really good. next week we'll be back at .6 ish .
0 · Reply
IamFullBull
IamFullBull Mar. 13 at 4:55 PM
$FEMY Run it.
0 · Reply
steve04240
steve04240 Mar. 13 at 4:19 PM
$FEMY
0 · Reply
TwizzlersForSale
TwizzlersForSale Mar. 13 at 2:27 PM
$FEMY For all the long term investors who are here on this thread, I want to remind you that - as you continuously increase your shares — you’re supporting FEMY with your finances, investing into their brand, company and future. I hope they take the funds and do a tremendous work, multiplying your future, and allowing new costs to sit on new investors who doubted.
0 · Reply
steve04240
steve04240 Mar. 13 at 2:11 PM
$FEMY got more! 🤑
0 · Reply
VanHousen22
VanHousen22 Mar. 13 at 2:06 PM
$FEMY I've been slowly building a modest position over the last few months. Thanks for all the insight
0 · Reply
Latest News on FEMY
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 27, 2026, 5:26 PM EST - 16 days ago

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

Feb 23, 2026, 9:00 AM EST - 20 days ago

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Jan 13, 2026, 9:00 AM EST - 2 months ago

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Dec 18, 2025, 9:15 AM EST - 3 months ago

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

Nov 25, 2025, 9:15 AM EST - 3 months ago

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PMCB

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Nov 3, 2025, 8:30 AM EST - 4 months ago

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Oct 16, 2025, 9:00 AM EDT - 5 months ago

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Sep 11, 2025, 9:00 AM EDT - 6 months ago

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Sep 8, 2025, 9:00 AM EDT - 6 months ago

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Aug 25, 2025, 11:44 PM EDT - 7 months ago

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Femasys Announces Second Quarter Financial Results for 2025

Aug 8, 2025, 4:05 PM EDT - 7 months ago

Femasys Announces Second Quarter Financial Results for 2025

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Aug 6, 2025, 9:00 AM EDT - 7 months ago

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Jul 1, 2025, 9:00 AM EDT - 9 months ago

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Jun 25, 2025, 9:00 AM EDT - 9 months ago

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Jun 17, 2025, 9:00 AM EDT - 9 months ago

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Jun 11, 2025, 9:00 AM EDT - 9 months ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

May 29, 2025, 4:23 PM EDT - 10 months ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

May 8, 2025, 5:01 PM EDT - 11 months ago

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Mar 27, 2025, 9:00 AM EDT - 1 year ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Mar 19, 2025, 9:20 AM EDT - 1 year ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Mar 18, 2025, 9:00 AM EDT - 1 year ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 25, 2025, 9:20 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Feb 11, 2025, 9:00 AM EST - 1 year ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 30, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Jan 16, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 26, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Nov 12, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Femasys Announces Infertility Clinic Customers from Coast to Coast

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Aug 29, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 17, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

May 16, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 9, 2024, 8:30 AM EDT - 2 years ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

May 7, 2024, 8:30 AM EDT - 2 years ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Apr 18, 2024, 8:30 AM EDT - 2 years ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Mar 21, 2024, 9:00 AM EDT - 2 years ago

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Mar 20, 2024, 8:15 AM EDT - 2 years ago

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Mar 6, 2024, 9:00 AM EST - 2 years ago

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Feb 28, 2024, 9:00 AM EST - 2 years ago

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

isthisonebetter
isthisonebetter Mar. 15 at 3:59 PM
$FEMY they had $4.5 mln in cash sept 30 and that’s roughly their quarterly burn. Have they completed a raise recently?
0 · Reply
TwizzlersForSale
TwizzlersForSale Mar. 14 at 5:42 PM
FEMY is beginning to set off price alerts on trader trackers with the recent price action we saw last week. Could get ugly very quickly with shorts having to cover as attention towards FEMY retail is slowly ramping up. Very nasty week/s ahead could trigger off short squeeze on catalysts or any updates from company. Stay tuned $FEMY
1 · Reply
steve04240
steve04240 Mar. 14 at 4:05 PM
$FEMY
0 · Reply
frchmn
frchmn Mar. 14 at 9:54 AM
$BRTX something is brewing here, similar to $SRXH and $FEMY . The 1H chart is telling. I have bags in all 3 after cutting some of my other bags.
0 · Reply
frchmn
frchmn Mar. 13 at 5:02 PM
$FEMY looks really good. next week we'll be back at .6 ish .
0 · Reply
IamFullBull
IamFullBull Mar. 13 at 4:55 PM
$FEMY Run it.
0 · Reply
steve04240
steve04240 Mar. 13 at 4:19 PM
$FEMY
0 · Reply
TwizzlersForSale
TwizzlersForSale Mar. 13 at 2:27 PM
$FEMY For all the long term investors who are here on this thread, I want to remind you that - as you continuously increase your shares — you’re supporting FEMY with your finances, investing into their brand, company and future. I hope they take the funds and do a tremendous work, multiplying your future, and allowing new costs to sit on new investors who doubted.
0 · Reply
steve04240
steve04240 Mar. 13 at 2:11 PM
$FEMY got more! 🤑
0 · Reply
VanHousen22
VanHousen22 Mar. 13 at 2:06 PM
$FEMY I've been slowly building a modest position over the last few months. Thanks for all the insight
0 · Reply
goldenxb
goldenxb Mar. 13 at 1:26 PM
$FEMY I’m enjoying the fact that they’re posting a shit ton more lately!!! Keep it going
1 · Reply
onethestiff
onethestiff Mar. 13 at 11:57 AM
$FEMY
0 · Reply
Bluesir
Bluesir Mar. 13 at 10:59 AM
$FEMY getting closer to ER. I have a goof feeling for today. Could cross 0,60 and maybe getting around 0,80 in the next days just before ER. Then ER should send us over 1$. This is more than a ‘wishful thinking’ believe me! GLA 👍🤞😎
1 · Reply
steve04240
steve04240 Mar. 12 at 3:21 PM
$FEMY someone hit the ask and send it!
1 · Reply
steve04240
steve04240 Mar. 12 at 12:13 PM
$FEMY
0 · Reply
ViGx
ViGx Mar. 12 at 11:59 AM
$FEMY https://hubs.li/Q046cDSV0
0 · Reply
steve04240
steve04240 Mar. 12 at 11:24 AM
$FEMY a little pre-market level 2 look
0 · Reply
frchmn
frchmn Mar. 12 at 5:41 AM
$FEMY .58 overnight? Nice
0 · Reply
steve04240
steve04240 Mar. 11 at 10:46 PM
$FEMY I call .60+ tomorrow
0 · Reply
traderswedenfab
traderswedenfab Mar. 11 at 10:33 PM
$FEMY , There is lots of sellers at 0.57 a very difficult wall to break. I expect no news coming soon except earnings but we all know after earning the price lowers by 10% 10/13 of times.
1 · Reply
steve04240
steve04240 Mar. 11 at 7:41 PM
$FEMY Lets get through this
1 · Reply
steve04240
steve04240 Mar. 11 at 6:37 PM
$FEMY seeing a pretty solid floor here the only way I see is up
0 · Reply